NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SGRL · data 2026-10-31
Shree Ganesh Remedies Ltd.
In plain words
Price: 17.7% below its 52-week high of ₹749.85.
Delivery: 55.0% of traded shares were kept for delivery over the last 10 sessions, against 60.9% over the last 52.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹99 cr |
| Net profit (last 12 months) | ₹15 cr |
| Sales growth, 3 years (yearly) | 6.6% |
| Profit growth, 3 years (yearly) | 1.4% |
At a glance
P/E 51.3, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 11.5%, ROCE 14.4%, operating margin 20.8%: how much profit it earns on the money it uses.
Debt/equity 0.19, Profit growth 1.4% and sales growth 6.6% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Healthy operating margin (20.8%).
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 55.3% over the last 20 sessions vs 59.4% in the 40 before (0.93x); shares delivered per day 0.38x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Shree Ganesh Remedies Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.19.
What is Shree Ganesh Remedies Ltd.'s P/E ratio?
About 51.3, based on the last 12 months' earnings and a price of ₹617.25 (data 2026-10-31).
What is the 52-week high and low of Shree Ganesh Remedies Ltd.?
The 52-week high is ₹749.85 and the 52-week low is ₹477.05.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Shree Ganesh Remedies Ltd. | ₹617.25 | ₹792 cr | 51.3 | — | 11.5% | 14.4% | 0.19 | +24.7% |
| Sudarshan Pharma Industries Ltd | ₹36.42 | ₹895 cr | 31.1 | 4.7 | 16.3% | 28.8% | 1.84 | +7.7% |
| Themis Medicare Limited | ₹94.83 | ₹875 cr | 21.9 | — | 0.3% | -2.3% | 0.25 | -24.0% |
| Anuh Pharma Limited | ₹87.31 | ₹873 cr | 15.7 | — | 12.1% | 17% | 0 | -1.1% |
| Kilitch Drugs (India) Limited | ₹201.32 | ₹703 cr | 23 | — | 12.5% | 12.3% | 0.32 | +1.5% |
| Valiant Laboratories Ltd. | ₹128.4 | ₹695 cr | 43.5 | — | -1.2% | 0.2% | 0.15 | +48.6% |
Compare SGRL with SUDARSHAN in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SGRL in NSE Scanner →